TQB-2252

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameTQB-2252
Drug Alias NameTQB2252TQB-2252
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsProgrammed cell death protein 1 blockers
TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes TQB-2223Penpulimab
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesChia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesChia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A